Basic Immunology
Oxford has fantastic strength in basic immunology research.
Oxford has a wonderful history in immunology research, including determining the structure of antibodies and uncovering the function of lymphocytes. The foundation for understanding human immune disorders and infection is built on the knowledge gained from basic research.
DEPARTMENTS IN THIS THEME
- Nuffield Department of Clinical Medicine
- Department of Zoology
- Radcliffe Department of Medicine
- Sir William Dunn School of Pathology
- Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences
- Nuffield Department of Surgical Sciences
- Department of Biochemistry
- Department of Physiology, Anatomy and Genetics
Recent publications
Click here to view recent publications from this themeWhat's new
New discovery furthers our understanding of how critical immune cells are controlled during an infection
9 November 2023
A recent publication from Research from the Gerard Lab in Kennedy Institute of Rheumatology looks at how a specific protein, called IFNγ, can coordinate CD8+ T cell responses during a flu infection.
Newly discovered cells could be responsible for atherosclerosis complications
3 July 2023
A new type of macrophages recently identified in atherosclerotic lesions could provide a missing link in understanding the inflammatory origins of the common yet fatal condition.
Communication at the crossroads of the immune system
6 February 2023
In his inaugural article in the Proceedings of the National Academy of Sciences as an NAS member (elected 2021), Prof Mike Dustin and his research team in Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences have explained how messages are passed across the immunological synapse. The research could have implications for future vaccine development and immunotherapy treatments.
Leducq Foundation grant boosts cardiovascular research
11 October 2022
The Leducq Foundation has awarded $7.5 million to researchers at the University of Oxford and their collaborators to advance immunotherapy as a treatment for cardiovascular disease, the leading cause of death in the UK.